In a significant expansion move, Perpetua Life Biotech, a US-based trailblazer in gerontology and longevity medicine, announces the formation of Perpetua Life Biotech UK Ltd. This new establishment in the UK aims to improve local accessibility and build collaborative relationships with British businesses and retailers.
Established in 2017 by three post-grad biology students from Boston College, Perpetua Life Biotech set out to fill a niche in the life extension market. After extensive research and development, their flagship product, AEON, was introduced in 2021. Dr. Michael Morgan, CEO of Perpetua Life Biotech, explains: “AEON was created to be an all-in-one longevity focused supplement. Each compound chosen for its stand-alone benefits as well as its synergistic ones paired with the other 10”.
Dr. Morgan also mentioned ongoing research involving compounds like Metformin, Low dose Naltrexone, and Rapamycin (Sirolimus), which are showing promising results in extending life.
In the realm of food supplements, substances such as Nicotinamide Mononucleotide (NMN), Nicotinamide Riboside (NR), Trans-Resveratrol, Fisetin, Astragalus, Quercetin, and Spermidine are highlighted, with over 1,000 published research papers supporting their anti-aging and anti-inflammatory benefits.
The launch of Perpetua Life Biotech UK Ltd. marks a pivotal move to directly serve the UK market. Previously, UK customers of the US company faced issues like long delivery times and high customs fees. The establishment of a UK presence resolves these challenges, offering British customers a more efficient and economical service.
Perpetua Life Biotech UK Ltd. is already planning to expand into the EU, aiming for local distribution to enhance product availability across Europe.
Dr. Michael Morgan, CEO, shared his enthusiasm about this new endeavour, saying, “We are excited to embark on this new chapter for Perpetua Life Biotech with the establishment of Perpetua Life Biotech UK Ltd. The UK’s standing as an innovation hub in life sciences perfectly complements our mission to develop transformative biotechnological solutions.”
Dr. Morgan concludes: “Despite very exciting developments in the anti-aging space we should not lose track of what can be done right now to combat the aging process. The importance of regular exercise, fasting, quality sleep, a healthy diet, and stress alleviation are vital components in fighting aging.”
Perpetua Life Biotech’s commitment to advancing longevity research on a global scale is further reinforced by the launch of its UK subsidiary, highlighting the company’s dedication to making innovative and accessible solutions available for healthy aging.
2024 promises to be a year of continued exciting developments from Perpetua Life for those keen on life extension research and progress.
For more details, visit https://www.perpetualife.uk
